Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year – BioSpace
Posted: October 10, 2020 at 8:03 am
ENGLEWOOD, CO / ACCESSWIRE / October 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs today reported financial results for its fiscal fourth quarter 2020, for the three month period ending June 30, 2020.
Fourth Quarter Fiscal 2020 Financial Highlights
Commenting on the fourth quarter of fiscal 2020, Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated "Revenue increased exponentially in Q4 2020, to $14.9 million, compared to $1.7 million for Q4 2019. It is important to note that this was the first full quarter of revenue from the combined Aytu and Innovus businesses, along with the Cerecor assets. Turning to the bottom line, adjusted EBITDA loss was reduced to just $1.7 million for Q4 2020, compared to a $3.7 million adjusted EBITDA loss for Q4 2019. On the balance sheet, with approximately $48.3 million in cash, cash equivalents and restricted cash after paying $15 million to fully extinguish the Deerfield balloon payment previously due January 2021, we have less than $1 million of debt, and at current spending levels, we believe we have sufficient runway to reach profitability."
Mr. Disbrow continued, "Taking a closer look at the top line, both of our revenue streams, from the Consumer Health and Rx segments, performed well. On the Consumer Health side, we generated $6.9 million in revenue, an increase compared to Q3. Contributing to those results was organic growth within our core Consumer Health product lines of diabetes care, sexual wellness and bladder health. Additionally, we strengthened our e-commerce business for Consumer Health. Furthermore, our newly launched Consumer Health product, Regoxidine, an over-the-counter foam formulation of minoxidil for hair regrowth, is on track to contribute revenue in excess of seven figures in its first twelve months from launch."
Mr. Disbrow added, "On the Rx side, revenue was $7.9 million, a significant increase compared to Q3. Contributing to Rx revenue was solid contribution from the pediatric franchise. Additional value was created with Natesto gaining preferred status on Express Scripts' national formulary and the Natesto spermatogenesis study results published in the Journal of Urology, both of which we expect to drive prescription growth in the coming quarters. Organic Rx growth was fueled by a relatively balanced contribution across our key products and improved sales execution. Despite the impact COVID has had on physician office access, Q4 represented a record revenue quarter for our Rx business and significant growth over the previous quarters. This is a strong statement about our field execution and clinical value of our products, and I'm pleased to see our call levels now picking back up to near normal in the current quarter to further drive prescription growth."
Mr. Disbrow concluded, "At $14.9 million in record quarterly revenue, with a narrowed Adjusted EBITDA loss, $48.3 million of cash, cash equivalents and restricted cash on the balance sheet, the addition of the Healight opportunity for COVID-19 and future potential non-COVID-19 applications, and our addition to the Russell 2000, we have strong momentum to grow shareholder value in fiscal 2021 and onward."
Conference Call Information
The company will host a live conference call at 4:30 p.m. ET today. The conference call can be accessed by dialing either:
877-407-9124 (toll-free)
201-689-8584 (international)
The webcast will be accessible live at https://www.webcaster4.com/Webcast/Page/2142/37506 and archived on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.
A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331 (international) and using the replay access code 37506.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The recently acquired Pediatric Portfolio includes (i) Cefaclor, a second-generation cephalosporin antibiotic suspension; (ii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iii) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distributes a COVID-19 IgG/IgM rapid test. This antibody test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. Aytu has also licensed the Healight Platform Technology. Healight is a pre-clinical investigational device being studied as a potential treatment for COVID-19 in severely ill, intubated patients and potentially other respiratory illnesses.
Aytu also operates a consumer health subsidiary, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty pharmaceutical company licensing, developing, and commercializing safe and effective consumer healthcare products designed to improve health and vitality. Innovus commercializes over twenty consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, our ability to successfully commercialize Healight Platform Technology, our ability to obtain FDA approval for the Healight Platform Technology, the effectiveness of the Healight Platform Technology in treating patients with COVID-19 or other illnesses, our ability to adequately protect the intellectual property associated with the Healight Platform Technology, regulatory delays, the reliability of the Healight Platform Technology in killing viruses and bacteria, market acceptance of UV based medical devices, the regulatory and commercial risks associated with introducing the COVID-19 rapid tests, any delays in shipment that may impact our ability to distribute the COVID-19 rapid tests, any reputational harm we may incur if there are delays in receiving the shipment of the COVID-19 rapid tests, our ability to enforce the exclusivity provisions of the distribution agreements, the reliability of serological testing in detecting COVID-19, shipping delays and their impact on our ability to introduce the COVID-19 rapid tests, the ability of the COVID-19 rapid tests to accurately and reliably test for COVID-19, the manufacturers of the COVID-19 rapid tests' ability to manufacture such testing kits on a high volume scale, manufacturing problems or delays related to the COVID-19 rapid tests, our ability to satisfy any labelling conditions or other FDA or other regulatory conditions to sell the COVID-19 rapid test kits, the demand or lack thereof for the COVID-19 rapid test kits, our ability to obtain additional COVID-19 rapid tests to meet demand, our ability to secure additional tests if the manufacturers of the COVID-19 rapid tests are unable to meet demand, the effects of the business combination of Aytu and the Pediatric Portfolio and the recently completed merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Pediatric Portfolio, the ultimate timing, outcome and results of integrating the operations the Pediatric Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization.
Contact for Media and Investors:
James CarbonaraHayden IR(646) 755-7412james@haydenir.com
Non-GAAP Financial Information
This press release contains a financial measure that does not comply with U.S. generally accepted accounting principles (GAAP), Non-GAAP Adjusted EBITDA. Non-GAAP Adjusted EBITDA excludes (i) amortization, (ii) depreciation, (iii) stock-based compensation, (iv) other expenses comprising net interest expense, (v) non-cash gains and/or losses recognized in the quarter or year due to changes in the fair value of certain of Aytu's financial liabilities, such as contingent consideration, derivative warrant liability, or certain exchanges of debt, (vi) bad debt expense, (vii) impairment of certain long-lived assets; (viii) one-time transaction costs and (ix) costs associated with the Company's Healight technology. Management believes these measures are useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. In addition, Aytu believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U.S. GAAP when understanding Aytu's operating performance. A reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below.
AYTU BIOSCIENCE, INC. AND SUBSIDIARIESConsolidated Statements of Operations
(Unaudited)
Three Months Ended June 30,
Revenues
Product revenue, net
License revenue, net
Total product revenue
Operating expenses
Cost of sales
Research and development
Selling, general and administrative
Selling, general and administrative - related party
Impairment of intangible assets
Amortization of intangible assets
Total operating expenses
Loss from operations
Other (expense) income
Other (expense), net
(Loss) / gain from change in fair value of contingent consideration
(Loss) on extinguishment of debt
Gain from warrant derivative liability
Total other (expense) income
Net loss
Weighted average number of shares outstanding ofcommon shares outstanding
Basic and diluted net loss per common share
AYTU BIOSCIENCE, INC. AND SUBSIDIARIESConsolidated Balance Sheets
Assets
Current assets
Cash and cash equivalents
Restricted cash
Accounts receivable, net
Inventory, net
Prepaid expenses and other
Other current assets
Total current assets
Fixed assets, net
Right-of-use asset
Licensed assets, net
Patents and tradenames, net
Product technology rights, net
Deposits
Goodwill
Total long-term assets
Total assets
AYTU BIOSCIENCE, INC. AND SUBSIDIARIESConsolidated Balance Sheets, Cont'd
Liabilities
Current liabilities
Accounts payable and other
Accrued liabilities
Accrued compensation
Debt
Contract liability
Current lease liability
Current portion of fixed payment arrangements
Current portion of CVR liabilities
Current portion of contingent consideration
Total current liabilities
Long-term contingent consideration, net of current portion
Long-term lease liability, net of current portion
Long-term fixed payment arrangements, net of current portion
Long-term CVR liabilities, net of current portion
Warrant derivative liability
Total liabilities
Read the rest here:
Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year - BioSpace
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020
- Male Hypogonadism Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2026 - Cheshire Media - December 6th, 2020
- Male Hypogonadism Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Astrazeneca Plc., Merck& Co. Inc.,... - December 6th, 2020
- Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for M... - UroToday - December 6th, 2020
- Prader-Willi Syndrome Facts: Causes, Diagnosis, Treatments and Prognosis - Gilmore Health News - December 6th, 2020
- Male Hypogonadism HRT Treatment Market 2020-28 booming segments, latest trends and analysis with Merck & Co, Allergan, Endo International,... - December 6th, 2020
- MLB notebook: Red Sox, Rodriguez agree to one-year, $8.3 million deal to avoid arbitration - pressherald.com - December 6th, 2020
- Impact of Covid-19 on Testosterone undecanoate Market is slated to grow rapidly in the forthcoming years with Key Players Bayer AG, Endo... - November 28th, 2020
- Estrogen in men: Symptoms of high and low levels, and more - Medical News Today - November 11th, 2020
- Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET - Stockhouse - November 11th, 2020
- Global Testosterone Replacement Therapy Market 2020 : Industry Analysis by Top Countries Data Definition, Size, Share, Segmentation and Forecast data... - November 11th, 2020
- Male Hypogonadism Therapy Market Forecast to 2027: Top Companies, Trends & Growth Factors and Trend Forecast to 2027 - TechnoWeekly - November 5th, 2020
- The Male Hypogonadism Market To Slither Amidst Covid-19, To Pick Up Pace Post-Covid-19, Reach US$ 3300 Mn - The Think Curiouser - November 5th, 2020
- Global Hypogonadism Drug Market Business Share, Industry Size and Future Investment Opportunities by 2026||ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly... - November 5th, 2020
- Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 - Press Release - Digital... - November 5th, 2020
- Global Hormone Replacement Therapy Market Recent Trends, Development, Growth and Forecast 2020-2027 - Eurowire - November 5th, 2020
- Andropause: Not the same as menopause but needs to be addressed - The Star Online - October 28th, 2020
- Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the... - October 28th, 2020
- Hormone Replacement Drugs Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026|Eli Lilly, Pfizer, AbbVie - Eurowire - October 28th, 2020
- The Anabolic Steroids market to go the reverse transversal way in the next decade - The Think Curiouser - October 25th, 2020
- EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market... - October 25th, 2020
- Male Hypogonadism Therapy Market is Booming Worldwide By Top Key Players: Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - October 13th, 2020
- Hormone Replacement Therapy Market Size, Trends, Growth, Key Companies, Forecast by 2026|Eli Lilly, Pfizer, AbbVie - Weekly Wall - October 13th, 2020
- Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 - Yahoo Finance - October 10th, 2020
- Sperm Take Up to 3 Years to Recover After Anabolic Steroids - Medscape - October 4th, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Shields Gazette - October 4th, 2020
- Testosterone Replacement Therapy Market 2020 Global Industry Sales, Industry Analysis with Top Countries Data, Share, Trends, Market Demand, Revenue,... - October 4th, 2020
- Treatment of the infertile couple - Contemporary Obgyn - October 4th, 2020
- Testosterone boosters: Uses and effectiveness - Medical News Today - September 22nd, 2020
- Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020 - Yahoo Finance - September 18th, 2020
- H.C. Wainwright Reiterated Lipocine Inc. [LPCN]. What else is Wall St. saying? - The DBT News - September 3rd, 2020
- Hormone Replacement Therapy Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the... - September 3rd, 2020
- Male Hypogonadism Market Estimated to be Driven by Innovation and Industrialization 2017 2026 - The News Brok - August 24th, 2020
- Male Hypogonadism Therapy Industry 2020 Market Size, Share, Price, Trend And Forecast To 2026- Industry Growth Insights - The Scarlet - August 24th, 2020
- Male Hypogonadism Market : Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors with Current Trends and Future Estimations -... - August 24th, 2020
- COVID-19 Impact On Hormone Replacement Therapy Market Size, Status And Forecast 2020-2026 - Galus Australis - August 14th, 2020
- Male Hypogonadism Therapy Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to 2027... - August 13th, 2020
- UB study finds testosterone therapy can lead to remission in men with Type 2 diabetes - UB Now: News and views for UB faculty and staff - University... - August 5th, 2020
- Male Hypogonadism Market 10-Year Market Forecast and Trends Analysis Research Report2017 2026 - The Daily Chronicle - August 4th, 2020
- UB diabetes expert's research shows testosterone therapy can lead to remission in men with Type 2 diabetes - UB News Center - July 31st, 2020
- Hormon replacement therapy Market Growth, Opportunities and Updated Business Strategies|Bayer Pharma - PharmiWeb.com - July 31st, 2020
- What are COVID-19 Impact on Male Hypogonadism Market? & what are Major Drives Which Boost Market Even In Outbreak? - WOLE TV - July 31st, 2020
- Testosterone Replacement Therapy and Its Potential Mental Health Benefits to Men - Press Release - Digital Journal - July 31st, 2020
- Global Testosterone Cypionate Market (Covid-19 Impact) Expected to Witness a Sustainable Growth over 2026 - Market Research Correspondent - July 31st, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - BioSpace - July 31st, 2020
- What is Male Menopause? Heres everything you need to know about andropause - PINKVILLA - July 26th, 2020
- North America Hormone Replacement Therapy Market: Demand, Share, Size, Industry Trends, Analysis and Forecast during 2020-2025 - Jewish Life News - July 3rd, 2020
- North America Hormone Replacement Therapy Market: Share, Industry Trends, Price, Size, Demand and Forecast to 2020-2025 - 3rd Watch News - July 3rd, 2020
- Testosterone undecanoate Market 2020 | What Will Be the Market Size and the Growth Rate Analysis by 2025? - Cole of Duty - July 1st, 2020
- Advancements in treatments in healthcare is boosting the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle - July 1st, 2020
- Global Hormone Replacement Therapy Market 2020 Research by Business Analysis, Growth Strategy and Industry Development to 2025 - Cole of Duty - July 1st, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - The Gardner News - June 22nd, 2020
- Human Chorionic Gonadotropin (hCG) Market Insights on Growth Trends, Top Players, Types, Applications and Regional Analysis - Personal Injury Bureau... - June 22nd, 2020
- Male Hypogonadism Therapy Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026 - CueReport - June 20th, 2020
- Emerging Opportunity in Transdermal Testosterone Market with Eminent Key Players and Future Outlook to 2024: AbbVie, Teva, Perrigo, Endo... - June 20th, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - Lexington Dispatch - June 20th, 2020
- Testosterone Gel Market: 2020 Industry Trends, Size, Growth Predictions, Segmentation, Business Statistics, Top Key Players and 2026 Forecast Research... - June 18th, 2020
- Anabolic Steroids Market to Witness Heightened Revenue Growth in the Next Decade - Owned - June 18th, 2020
- Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis... - June 14th, 2020
- QOL and body composition benefits seen with novel oral T treatment - Urology Times - June 14th, 2020
- Novel oral testosterone therapy shows liver health benefits - Urology Times - June 14th, 2020